David D. Chang - Feb 3, 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Feb 3, 2025
Transactions value $
-$77,285
Form type
4
Date filed
2/5/2025, 04:13 PM
Previous filing
Jan 28, 2025
Next filing
Mar 18, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Sale -$77.3K -46K -0.86% $1.68 5.32M Feb 3, 2025 Direct F1, F2
holding ALLO Common Stock 856K Feb 3, 2025 See footnote F3
holding ALLO Common Stock 856K Feb 3, 2025 See footnote F4
holding ALLO Common Stock 1.2M Feb 3, 2025 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.
F3 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F5 Securities held in the name of the Chang 2006 Family Trust